Researchers at University of California San Diego have found that the most common form of liver cancer—one with a high mortality rate—can be better targeted and treated using an innovative new stem cell-derived therapy, ...
Jul 9, 2024
0
29
A promising therapy that treats blood cancers by harnessing the power of the immune system to target and destroy cancer cells could now treat solid tumors more efficiently.
Jul 2, 2024
0
35
New study findings suggest that baby-led weaning—a popular method for introducing solid foods to infants—furnishes ample calories for growth and development. The findings provide evidence-based support for baby-led weaning, ...
Jul 1, 2024
0
1
While the overall five-year survival rate for pancreatic cancer is slowly improving, it remains discouragingly low—just 13%, according to the American Cancer Society. And the odds are even worse if the cancer is discovered ...
Jun 24, 2024
0
0
A team of Roswell Park Comprehensive Cancer Center experts led by Hemn Mohammadpour, DVM, Ph.D., has conducted research that offers new insights into tumor biology and may lay the groundwork for more effective cancer immunotherapy.
Jun 21, 2024
0
12
The U.S. Food and Drug Administration has approved Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor (TKI), for the treatment of patients with neurotrophic tyrosine receptor kinase (NTRK)-positive locally ...
Jun 21, 2024
0
0
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according ...
Jun 20, 2024
0
1
Immunotherapy is based on harnessing a person's own immune system to attack cancer cells. However, patients with certain tumors do not respond to these therapies and it remains unclear why.
Jun 4, 2024
0
33
Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form of kidney cancer with few treatment options; even with new immunotherapies, only around one in 10 patients ultimately survive.
Jun 4, 2024
0
0
Two early-phase clinical trials presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center demonstrate promising responses and safety ...
Jun 3, 2024
0
0
